Pharmacological prevention of second primary cancers: From chemoprevention to precision cancer interception

Cancer Treatment Reviews · Published 2026-08-03 · DOI 10.1016/j.ctrv.2026.103200

Authors (9)

Mylène Wespiser, Pauline Rochefort, Thibault Gauduchon, Clio Coste, Christophe Caux, Isabelle Ray-Coquard, Maurice Perol, Jean-Yves Blay, Pierre-Etienne Heudel

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Wespiser, M., Rochefort, P., Gauduchon, T., et al. (2026). Pharmacological prevention of second primary cancers: From chemoprevention to precision cancer interception. Cancer Treatment Reviews. https://doi.org/10.1016/j.ctrv.2026.103200

Related articles

• Screening and prevention of second primary cancers by hospital-based oncology professionals · European Journal of Cancer Prevention · 2026 · Cites or is cited by this article
• Targeting key epigenetic regulators in solid tumors: focus on EZH2, PRMT5, and BET inhibitors · Cancer Treatment Reviews · 2026 · Same journal
• Glioblastoma and resistance to radiotherapy: role of cancer stem cells subpopulations, hypoxia and therapeutic strategies · Cancer Treatment Reviews · 2026 · Same journal
• Circulating tumor DNA in breast cancer: From technological foundation to clinical implementation · Cancer Treatment Reviews · 2026 · Same journal
• Multigene assays in early breast cancer: Current evidence, limits and future directions · Cancer Treatment Reviews · 2026 · Same journal
• Cyclotherapy: exploiting cell-cycle decoupling for selective cancer cytotoxicity and normal-tissue protection · Cancer Treatment Reviews · 2026 · Same journal
• Cellular senescence: A novel mechanism of therapeutic resistance in prostate cancer · Cancer Treatment Reviews · 2025 · Same journal
• Is Cytoreductive surgery for unresectable colorectal liver metastases able to improve patient outcome? Results of a pilot prospective study · Cancer Treatment Reviews · 2026 · Same journal
• KRAS G12C-mutant non-small cell lung cancer: A practical guide for clinicians · Cancer Treatment Reviews · 2026 · Same journal
• Targeting HER2 in urothelial carcinoma: from pathway inhibition to antibody–drug conjugates · Cancer Treatment Reviews · 2026 · Same journal